Alector - Raised $215M Funding from 19 investors - Tracxn

Nov 5, 2024 · Alector has raised a total funding of $215M over 5 rounds from 19 investors. Investors include New Leaf Venture Partners, Foresite Capital and 17 others. Their latest …

CouponFollow Extension

$215
OFF

Alector - Raised $215M Funding From 19 Investors - Tracxn

1 week from now

Nov 5, 2024 · Alector has raised a total funding of $215M over 5 rounds from 19 investors. Investors include New Leaf Venture Partners, Foresite Capital and 17 others. Their latest …

tracxn.com

$215
OFF

Alector - Company Profile - Tracxn

1 week from now

Oct 19, 2024 · Alector - Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders. Public Company. Raised a total funding of $215M over 5 rounds …

tracxn.com

$215
OFF

Nauto - Raised $215M Funding From 15 Investors - Tracxn

1 week from now

Nov 5, 2024 · Nauto has raised a total funding of $215M over 5 rounds from 15 investors. Investors include Greylock, SoftBank Group and 13 others. Their latest funding round was of …

tracxn.com

$19.00
OFF

Alector - Funding, Financials, Valuation & Investors - Crunchbase

1 week from now

Feb 7, 2019 · Their latest funding was raised on Jan 17, 2024 from a Post-IPO Equity round. Alector is registered under the ticker NASDAQ:ALEC . Their stock opened with $19.00 in its …

crunchbase.com

$215
OFF

Alector - Company Profile - Tracxn

1 week from now

Alector - Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders. Public Company. Raised a total funding of $215M over 5 rounds from 19 investors. …

tracxn.com

$2
OFF

GSK, Under Pressure To Perform, Pens $2.2B Deal With Alector …

1 week from now

Jul 2, 2021 · Alector's work could have the same effect in neurodegeneration, moving away from the debates around tau and amyloid beta and instead embracing a unified theory of pathogen …

fiercebiotech.com

$36
OFF

Alector Reports First Quarter 2024 Financial Results And Provides ...

1 week from now

May 8, 2024 · Net Loss. For the quarter ended March 31, 2024, Alector reported a net loss of $36.1 million, or $0.38 per share, compared to a net loss of $45.9 million, or $0.55 net loss per …

alector.com

$50
OFF

Alector Secures Flexible Credit Facility For Up To $50 Million From ...

1 week from now

4 days ago · SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, …

alector.com

$45
OFF

Alector Reports First Quarter 2023 Financial Results And Provides ...

1 week from now

For the quarter ended March 31, 2023, Alector reported a net loss of $45.9 million, or $0.55 per share, compared to a net loss of $44.6 million, or $0.54 per share, for the same period in …

alector.com

$50
OFF

Alector Secures Funding To Advance Clinical Trials - Nasdaq

1 week from now

3 days ago · Alector ( (ALEC) ) has provided an update.Alector, a clinical-stage biotechnology company, has secured a $50 million credit facility from Hercules Capital. This funding boosts …

nasdaq.com

$215
OFF

Imply - Raised $215M Funding From 7 Investors - Tracxn

1 week from now

Imply has raised a total funding of $215M over 5 rounds from 7 investors. Investors include Bessemer Venture Partners, Khosla Ventures and 5 others. Their latest funding round was of …

tracxn.com

$114
OFF

AliveCor - Raised $114M Funding From 19 Investors - Tracxn

1 week from now

Nov 5, 2024 · Stream - Ramat Gan based, raised a funding of $30M in Series B round held on 22 Oct, 2024. AliveCor has raised a total funding of $114M over 8 rounds from 19 investors. …

tracxn.com

$19
OFF

Amalgam - Raised $19.5M Funding From 4 Investors - Tracxn

1 week from now

Oct 23, 2024 · Stream - Ramat Gan based, raised a funding of $30M in Series B round held on 22 Oct, 2024. Viseur - Ankara based, raised a funding in Seed round held on 22 Oct, 2024. …

tracxn.com

FAQs about Alector - Raised $215M Funding from 19 investors - Tracxn Coupon?

Will AbbVie pay Alector $250 million?

AbbVie’s exercise of that option would prompt a $250 million payment to Alector. Alector continues to advance Alector Brain Carrier (ABC), a proprietary, versatile blood-brain barrier (BBB) technology platform, which is being applied selectively to the company’s next-generation product candidates and research pipeline. ...

How much cash does Alector have in 2024?

As of March 31, 2024, Alector’s cash, cash equivalents and investments totaled $562.1 million. “Continuing the momentum built through the first quarter, Alector is well positioned to have an impactful year, supported by an extended cash runway that carries the company through 2026,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. ...

What makes Alector a great company?

We relish a challenge and bring a spirit of curiosity, empathy, and collaboration to our daily work. This mindset motivates and guides us as we forge new paths to deliver urgently needed, potentially first-in-class therapeutics. Alector is a biopharmaceutical company that develops therapies for the treatment of neurodegeneration diseases. ...

What does Alector do?

At Alector, we are on a mission to slow the progression of neurodegenerative diseases and one day prevent their occurrence. We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. ...

Where is Alector based?

A preclinical candidate using ABC technology to introduce GCase enzyme for treating Parkinson's disease and Lewy body dementia. Where is Alector's headquarters? Alector is located in San Francisco, California, United States. Who invested in Alector? ...

What's new at Alector?

Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development at Alector, added, “In addition to these encouraging research and development updates, Alector continues to strengthen its leadership team with executive and Board appointments. ...